DM-9384 · Evidence-based safety and harm-reduction overview.
| Also known as | DM-9384 |
| Category | Nootropic |
| chemical_family | Dimethylamino-substituted racetam analog |
| developer | Daiichi Sankyo (Japan) |
| US legal status | Not approved by FDA; sold gray-market in US. Marketed pharmaceutical in some Asian countries. |
Racetam congener; proposed to modulate GABA and acetylcholine neurotransmission. Nefiracetam differs from piracetam by inclusion of a dimethylamino group, theoretically enhancing bioavailability and blood-brain barrier penetration. Some studies suggested anxiolytic effects in addition to cognitive support.
Proposed to enhance both GABAergic and cholinergic neurotransmission via membrane modulation and receptor sensitization. May increase neuronal membrane plasticity and protect against excitotoxicity. Human mechanism of action remains largely theoretical.
Developed by Daiichi Sankyo and colleagues in Japan during the 1980s-1990s. Named DM-9384 in developmental phase. Approved as a pharmaceutical in Japan and some other Asian markets but never pursued for FDA approval or marketed in North America.
Several small studies in elderly populations and dementia; replication limited. Japanese clinical trials present but not widely reproduced. European and North American follow-up research minimal; most evidence is 1990s-era with methodological limitations.
Clinical trials used 300-600 mg daily in divided doses. Some studies employed higher doses up to 1000 mg daily. Gray-market products typically 300-500 mg per capsule; no consensus dosing exists.
This is general research/context information, not medical advice or a recommended protocol.
Anecdotal stacking with choline sources and other racetams reported but not tested in humans. GABA-modulating effects discourage combination with other GABAergic substances without medical guidance.
L-theanine and caffeine combination. Legal, safe, well-studied ingredients with evidence for improved focus and relaxed alertness without regulatory ambiguity.
See our recommended pickIf you are going to research a compound, verifying identity and purity is the single most protective step. Independent analytical testing and sterile-handling supplies reduce risk.
Compare testing optionsNo. It is not approved as a drug or dietary supplement in the United States, only available in gray market.
Primarily Japanese researchers in elderly and cognitive decline populations. Replication by Western research is limited.
Animal studies suggest GABAergic properties, but no rigorous human anxiety trials exist; claims of anti-anxiety benefit lack strong clinical support.
DM-9384 is the developmental code name for nefiracetam used by Daiichi Sankyo during pharmaceutical research.
Limited availability in some Asian countries and through gray-market online sources in the US and Europe; not legitimately marketed in North America.
Medical & legal disclaimer. This site is for informational and harm-reduction purposes only. It is not medical advice and is not a substitute for a licensed healthcare professional. The compounds discussed are largely not approved by the FDA for human use and many are sold strictly as research chemicals 'not for human consumption.' Nothing here is an endorsement to purchase, possess, or use any substance. Laws vary by jurisdiction. Always consult a qualified physician and follow the law where you live.
Some links on this page may be affiliate links. If you buy through them we may earn a commission at no extra cost to you. This never changes the safety information we publish.